We’re excited about Xeomin and the wider array of treatment options for frown lines that are now available to our patients. Xeomin will provide patients with another great option to enhance their cosmetic appearance.
Baltimore, MD (PRWEB) December 30, 2011
MDLSV now offering Xeomin for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines), months before the full national release, due to the elite status and extensive experience of MDLSV’s physicians.
The US Food and Drug Administration recently approved XEOMIN for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.
Like Botox and Dysport, Xeomin works by blocking nerve signals to the muscles that cause facial wrinkles. What makes Xeomin unique is that all proteins have been removed other than the basic muscle relaxant. Xeomin is pure botulinum toxin type A. This greatly lessens the chance of an allergic reaction to injection.
“We’re excited about Xeomin and the wider array of treatment options for frown lines that are now available to our patients,” says Dr. Margaret Weiss, “We’re proud to offer our introductory supply of Xeomin to our patients before it it is officially launched by Merz Aesthetics next Spring.” Dr Robert Weiss added "Xeomin will provide patients with another great option to enhance their cosmetic appearance."
Xeomin® has been available in many countries since 2005, and was recently approved by the FDA for use in the US. It will be made available to most physicians starting in March 2012, but the elite status and extensive experience of MDLSV's physicians earned them early access to a limited supply of Xeomin®. They have been treating patients with Xeomin since November 2011.
Xeomin is manufactured by Merz Aesthetics, the makers of Radiesse.
The Maryland Laser, Skin and Vein Institute is a cosmetically oriented dermatology practice, originated by Drs. Robert & Margaret Weiss over 20 years ago, based in Hunt Valley (Baltimore), MD. The MDLSV Institute not only treats thousands of patients per year, but is a leading clinical research facility investigating new skin treatments and devices for the purposes of FDA clearance and improving patient treatments and outcomes.